Association of Multiple Medications With the Severity of Dyspepsia

Overview

Dyspepsia is a very common gastrointestinal disease. Some medications, were associated with higher frequent incidences of dyspepsia, including non-steroid anti-inflammatory drugs (NSAIDs), Bisphosphonates, Tetracyclines, et al. Multiple medications were suggested to be strongly relate to adverse drug events (ADEs), adverse drug reactions (ADRs), drug-drug interactions, and drug-disease interactions, which may cause gastrointestinal(GI) dysfunction or injury to the GI mucosa. However, it was unclear whether multiple medications was associated with more severe symptoms of dyspepsia and dyspepsia-based score systems.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2023

Clinical Trial Outcome Measures

Primary Measures

  • The rate of patients with severe dyspepsia judged by patients
    • Time Frame: 1 day
    • Patients rated the severity of dyspepsia as mild, moderate, and severe by themselves

Secondary Measures

  • Global Overall Symptom score (GOSS)
    • Time Frame: 1 days
    • The GOSS consists of 10 cardinal items (epigastric pain, epigastric discomfort, Heartburn, acid regurgitation, upper abdominal bloating, belching, nausea, early satiety, postprandial fullness, other epigastric symptoms(eg. epigastric burning). Each item can be scored from 1 (no) to 7 (worst).
  • Functional dyspepsia
    • Time Frame: 1 days
    • Functional dyspepsia was defined by Rome IV criteria. Patients diagnosed as Rome IV criteria met the following criteria: by one or more of the following symptoms: postprandial fullness, early satiation, epigastric pain, and epigastric burning that are unexplained after a routine clinical evaluation, Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis.
  • organic upper gastrointestinal (GI) diseases.
    • Time Frame: 1 day
    • All included patients underwent upper GI endoscopy and abdominal ultrasound and H. Pylori test. Barrett’s esophagus, esophageal candidiasis, esophageal cancer, gastric ulcer, gastric erosion, gastric cancer, duodenal ulcer, duodenal erosion, cholecystitis, pancreatitis and biliary stones were classified as organic upper GI diseases.
  • subtypes of functional dyspepsia
    • Time Frame: 6 months
    • functional dyspepsia was classified into three subgroups:(1) Postprandial Distress Syndrome, defined as Bothersome postprandial fullness or/and Bothersome early satiation. (2) Bothersome epigastric pain AND/OR Bothersome epigastric burning. (3) mixed syndrome, defined when postprandial distress syndrome and epigastric pain syndrome presented simultaneously.
  • Short Form of Nepean Dyspepsia Index (SF-NDI)
    • Time Frame: 1 day
    • The SF-NDI consists of 10 questions regarding the effects of dyspepsia symptoms (“stomach problems”) on different aspects of life (tension, interference with daily activities, eating/drinking, knowledge/control, and work/study). Each response can be from 1 (not at all affected) to 5 (extremely affected), or 0 (N/A), for a total summed score out of 50.
  • Hospital anxiety and depression scale
    • Time Frame: 1 day
    • Anxiety and depression of patients are assessed by using Hospital Anxiety and Depression Scale.It contains 14 items (7 anxiety and 7 depression), which assess symptoms experienced during the past week on a 0-3 scale. A subscore of > 8 for depression or anxiety would indicate a clinical case.
  • Quality of Life scores
    • Time Frame: 1 day
    • Quality of Life scores assessed by Patient-reported outcomes measurement information system (PROMIS) Global-10 questionnaire.PROMIS Global-10 is a newly validated 10-question survey used to assess health care-related quality of life measures for the general population. It’s a 10-item patient-reported questionnaire in which the response options are presented as 5-point (as well as a single 11-point) rating scales. These scores are then standardized to the general population, using the “T-Score”. The average “T-Score” for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient and a better quality of life.
  • Number of Participants with other functional gastrointestinal diseases
    • Time Frame: 1 day
    • Other functional gastrointestinal diseases,such as irritable bowel syndrome(IBS) or functional heartburn,etc.
  • Functional dyspepsia symptom diary (FDSD) score
    • Time Frame: 1 days
    • The FDSD consists of 5 cardinal items (burning in the stomach, stomach pain, bloating, postprandial fullness, and early satiety) and 3 supplementary items (nausea, burping/belching rating, and burping/belching bother). Each item can be scored from 0 (no) to 10 (worst). Total Symptom Score includes the 5 cardinal items and ranges from 0 to 50

Participating in This Clinical Trial

Inclusion Criteria

1. aged ≥18 years old 2. Patients who met broad criteria of dyspepsia Exclusion Criteria:

1. organ failure defined by Marshall standard 2. severe psychiatric illnesses 3. suspected or identified bowel obstruction 4. known malignancy 5. pregnancy or lactation 6. unable to provide consent

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Air Force Military Medical University, China
  • Provider of Information About this Clinical Study
    • Principal Investigator: Yanglin Pan, professor – Air Force Military Medical University, China
  • Overall Contact(s)
    • Yanglin Pan, 13991811225, yanglinpan@hotmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.